Coldstream Capital Management Inc. Decreases Position in West Pharmaceutical Services, Inc. (NYSE:WST)

Coldstream Capital Management Inc. decreased its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 1.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,617 shares of the medical instruments supplier’s stock after selling 44 shares during the quarter. Coldstream Capital Management Inc.’s holdings in West Pharmaceutical Services were worth $862,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Fidelis Capital Partners LLC purchased a new stake in West Pharmaceutical Services during the first quarter worth approximately $27,000. Crewe Advisors LLC lifted its stake in West Pharmaceutical Services by 322.7% in the second quarter. Crewe Advisors LLC now owns 93 shares of the medical instruments supplier’s stock valued at $31,000 after buying an additional 71 shares during the last quarter. Quarry LP lifted its stake in West Pharmaceutical Services by 155.3% in the fourth quarter. Quarry LP now owns 97 shares of the medical instruments supplier’s stock valued at $34,000 after buying an additional 59 shares during the last quarter. Hazlett Burt & Watson Inc. purchased a new stake in West Pharmaceutical Services in the first quarter valued at approximately $40,000. Finally, Northwest Investment Counselors LLC purchased a new stake in West Pharmaceutical Services in the first quarter valued at approximately $40,000. Hedge funds and other institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Price Performance

Shares of NYSE WST opened at $302.35 on Thursday. The company has a current ratio of 2.34, a quick ratio of 1.68 and a debt-to-equity ratio of 0.03. West Pharmaceutical Services, Inc. has a twelve month low of $265.00 and a twelve month high of $413.70. The stock has a 50 day moving average of $306.18 and a two-hundred day moving average of $340.02. The stock has a market cap of $22.02 billion, a P/E ratio of 39.89, a P/E/G ratio of 10.60 and a beta of 1.01.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings data on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.22). West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 19.17%. The firm had revenue of $702.10 million during the quarter, compared to analysts’ expectations of $729.36 million. During the same quarter in the prior year, the firm posted $2.11 EPS. West Pharmaceutical Services’s quarterly revenue was down 6.9% compared to the same quarter last year. On average, research analysts forecast that West Pharmaceutical Services, Inc. will post 6.42 earnings per share for the current year.

Insider Activity

In other news, VP Charles Witherspoon sold 1,029 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $300.00, for a total value of $308,700.00. Following the transaction, the vice president now owns 1,478 shares of the company’s stock, valued at $443,400. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.53% of the company’s stock.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.